ATUM today announced a distribution partnership with Trio Biotech, Co Ltd. (TrioBio) to market and promote ATUM’s unique Leap-In Transposase® platform in China. ATUM’s Leap-In platform offers bioengineering solutions for efficient cell line development, genome engineering, and robust production of pharmaceutical biologics.
TrioBio is well established in China as the premier distributor of life science tools and instruments to facilitate cell imaging, clonality validation, and automated cell plating and tracking. With locations in Shanghai and Beijing and deep expertise in cell line development, TrioBio is poised to bring the Leap-In Transposase platform to Chinese pharmaceutical companies seeking support in their manufacturing of protein pharmaceuticals, viral drug delivery vehicles, and cell-based drugs.
The global biologics pharmaceutical market is rapidly approaching a quarter of a trillion USD per year, with China being one of the fastest growing geographies. Despite the success of biologics as drugs, building and engineering mammalian cell lines producing these pharmaceuticals is a significant manufacturing bottleneck adding time and cost to the production process. ATUM’s Leap-In Transposase platform enables rapid, robust, and efficient manufacturing of high-quality protein pharmaceuticals. The Leap-In platform has already been licensed by a majority of the top 20 global pharmaceutical companies and, as of today, has enabled 16 Investigational New Drug (IND) Applications to be filed and approved by three regulatory authorities, with many more approvals expected within the next few months. Authorities that have approved Leap-In-enabled INDs include the Chinese National Medical Products Administration (NMPA), the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
“We are excited to bring ATUM’s innovative biomanufacturing approaches to China through TrioBio,” said Jeremy Minshull, Ph.D., CEO and cofounder of ATUM, “The protein therapeutics manufacturing market in China represents a significant opportunity for ATUM. TrioBio’s outstanding customer-centered reputation makes them the natural choice as ATUM’s partner to provide services and support tailored to Chinese manufacturing needs.”
About ATUM
ATUM offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and cellular engineering and production. The company exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster. For more information please visit: www.atum.bio.
About TrioBio
TrioBio is a China-based distributor with offices in Shanghai and Beijing. Continuously we strive to provide local customers with cutting-edge instrumentations and professional services in the field of life sciences. We focus on the biopharmaceutical market and maintain long-term cooperative relationships with clients. For more information, please visit: www.trio-biotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005449/en/
Contacts
Colin Sanford
colin@bioscribe.com
